Canertinib represents the very first TKI proven to interact with ABCG2 in an inhibitory way [17]. Then, other different tyrosine kinase inhibitors structurally related to canertinib, including pelitinib [14], and ceritinib [34], have become new multitarget reversers of ABCB1-, ABCC1-, ...